Key result
Roux-en-Y gastric bypass surgery led to a 35 kg weight loss (P<0.0001), decreased late OGTT plasma glucose, and an 84% increase in β-cell secretion correlated with a 29-fold elevation in GLP-1.
Why the study?
Does Roux-en-Y gastric bypass surgery improve whole-body insulin sensitivity and beta-cell function in nondiabetic morbidly obese patients?
Population
18 subjects total: 6 nondiabetic, morbidly obese patients, 6 matching obese controls, and 6 lean controls.
Comparison
Roux-en-Y gastric bypass (RYGB) surgery vs Matching obese controls and lean controls
Design
Cohort
Follow-up
7 ± 1 months
Authors
Loading...
RYGB may alter β-cell function and glucose turnover in nondiabetic obesity; leaves open clinical relevance and durability.
Observational (n=18)
Does Roux-en-Y gastric bypass surgery improve whole-body insulin sensitivity and beta-cell function in nondiabetic morbidly obese patients?
RYGB surgery in morbidly obese patients significantly increases GLP-1 release and beta-cell function, improving insulin sensitivity to levels comparable to obese controls.
Anderwald et al. (2012) conducted an observational in Nondiabetic, morbidly obese (n=18). Roux-en-Y gastric bypass (RYGB) surgery vs. Pre-operative state, obese controls, and lean controls was evaluated on β-cell function, glucose turnover, whole-body insulin sensitivity, and gastrointestinal glucose absorption. Roux-en-Y gastric bypass surgery led to a 35 kg weight loss (P<0.0001), decreased late OGTT plasma glucose, and an 84% increase in β-cell secretion correlated with a 29-fold elevation in GLP-1.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: